WASHINGTON — The Pentagon has awarded a Singapore-based pharmaceutical company nearly $41 million to develop ketamine wafers for wounded troops, pursuing a treatment that could reach the battlefield through emergency authorization before full Food and Drug Administration approval.

The sole-source development award to iX Biopharma supports Wafermine, a drug designed to dissolve under the tongue and treat moderate to severe acute pain.

But the effort faces questions about manufacturing readiness. Defense News reported Oct. 22, citing a Politico investigation, that the company’s proposed U.S. manufacturing partner lacked the Nevada license required to operate.

The public record describes a development program with regulatory and production steps still ahead. Its significance lies in both the medical need it seeks to address and the government’s responsibility to establish that the treatment can be safely manufactured, authorized and delivered.

What the $41 million Pentagon ketamine contract covers

iX Biopharma disclosed the $40.95 million award Feb. 12. The 36-month program, funded through the Defense Health Agency Contracting Activity, supports clinical development and work toward emergency authorization.

The company attributed its sole-source selection to its technology, development progress and ability to meet government requirements. Its announcement describes monthly payments and cost reimbursements; the award value is not a record of money already paid.

Sole-source contracting is permitted under specified circumstances. For example, federal acquisition rules allow awards without full and open competition when only one responsible source can satisfy an agency’s requirements, subject to justification and other conditions.

The company’s announcement does not establish which contracting authority governed this particular award or reproduce the Pentagon’s complete justification. Assessing the selection and price would require those government records. The absence of competitive bidding alone does not establish wrongdoing.

Why the military wants a wafer

Wafermine’s proposed advantage is its delivery method. The company says the wafer allows ketamine to enter the bloodstream through tissue under the tongue, avoiding the need for an injection or intravenous access.

That design addresses a problem the Defense Health Agency identifies in its battlefield pain program: providing rapid pain relief during field care and evacuation, including when casualties require prolonged treatment before reaching higher-level care.

The agency describes an effort to develop nonopioid medicines, including ketamine, suitable for those conditions. It also identifies an existing medication that can be administered without an IV, underscoring that Wafermine would enter an established field of battlefield pain treatments.

Whether this particular formulation offers sufficient benefits, and under what conditions it should be used, remains a question for clinical evidence and regulatory review.

Ketamine already has a battlefield role

The military’s use of ketamine predates this contract.

A study of Department of Defense Trauma Registry records examined 5,965 patients and 8,607 pain-medication administrations during U.S. military operations from 2010 through 2019.

Ketamine’s annual share of those administrations rose from 14.2% to 52.6%, while the opioid share declined from 85.8% to 47.4%. Among patients who received a single pain-medication dose, those given ketamine had more severe injuries on average.

The researchers described ketamine as an increasingly used treatment for combat casualties. Their retrospective analysis establishes experience with the drug, but it does not demonstrate that Wafermine itself is safe or effective.

Ketamine also has effects beyond pain relief. The study describes dose-dependent effects that can include dissociation and amnesia. The medical history supporting interest in the drug does not eliminate the need to evaluate a new formulation and its proposed use.

The emergency declaration opens a regulatory path

A federal notice published Sept. 3 provides the legal foundation for considering emergency battlefield pain treatments.

According to the notice, the Pentagon determined July 15 that a military emergency, or a significant potential for one, involved heightened risks to U.S. forces. Health and Human Services Secretary Robert F. Kennedy Jr. issued the corresponding declaration Aug. 31.

Its scope includes casualties associated with chemical, biological, radiological and nuclear agents, as well as conventional combat weapons, including firearms, projectiles and explosives. It addresses moderate to severe acute pain and risks such as shock and respiratory distress.

The notice does not name Wafermine, identify a specific impending operation or authorize a particular medication. It permits the FDA to consider individual emergency authorizations under the applicable statutory requirements.

Under FDA guidance on emergency use authorization, the agency must assess whether a product may be effective, whether its known and potential benefits outweigh its risks, and whether an adequate, approved and available alternative exists.

That evidentiary standard differs from full approval. The guidance also calls for information about manufacturing sites and their compliance with manufacturing requirements.

Nevada manufacturing remains a central issue

The proposed production arrangement involves Orion Specialty Labs LLC in Henderson, Nevada.

In a June 15 filing with the Singapore Exchange, iX Biopharma announced plans to move a freeze dryer, packaging line and other equipment from Croydon, Australia, to Orion’s facility.

The company said U.S. manufacturing was required to fulfill the government contract and described the move as a way to accelerate production.

State records document an earlier licensing obstacle. Nevada State Board of Pharmacy minutes from March show Orion’s outsourcing-facility application was tabled after testimony and questions from board members.

Those minutes establish what happened in March; they do not independently establish Orion’s current licensing status. The more recent assertion that the necessary license remained outstanding comes from the October reporting.

The commercial arrangement also remained unfinished in the company’s Oct. 10 shareholder update. iX Biopharma said it was still negotiating final terms for the proposed Orion joint venture.

These records leave questions about production readiness. They do not establish that troops have received improperly manufactured medicine or that a contractual delivery deadline has been missed.

Company filings give different submission windows

The company’s public statements also warrant a closer look at timing.

In its Sept. 7 announcement, iX Biopharma said it expected to complete its emergency-use application in the fourth quarter of 2026. It also described the possibility of military sales before full approval.

The Oct. 10 shareholder update used a broader window, saying the company anticipated completing the application within the next 12 months. It described preparatory studies as underway and an FDA meeting as a step preceding two planned Phase 3 trials.

The later statement does not explicitly withdraw the year-end target or announce a delay. Both windows could accommodate a submission this year. It nevertheless provides less precise guidance about when the application will be finished. Neither filing establishes that the FDA has authorized Wafermine.

Readiness depends on more than an award

The effort belongs within a broader discussion of how the military prepares to function when normal support becomes difficult. USA Herald’s reporting on FORTRESS America and wartime infrastructure disruption examines that problem at military installations. Battlefield medicine addresses the consequences for casualties when treatment and evacuation are constrained.

The contract and emergency declaration show government support for developing a new pain-treatment option. Establishing its operational value will require evidence about clinical performance, manufacturing readiness and delivery.

The outstanding records matter: the Pentagon’s contracting justification, payment and milestone information, an updated state licensing determination, and any FDA authorization specifying how the drug may be used.

For wounded service members, the practical measure of success will be whether the program delivers a dependable treatment that medical personnel can use safely under battlefield conditions.